{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:23:42Z","timestamp":1791829422246,"version":"4.3.4"},"reference-count":49,"publisher":"Japan Atherosclerosis Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.5551\/jat.44818","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T22:26:05Z","timestamp":1530224765000},"page":"1255-1273","source":"Crossref","is-referenced-by-count":3,"title":["Clinical and Economic Analysis of Lipid Goal Attainments in Chinese Patients with Acute Coronary Syndrome Who Received Post-Percutaneous Coronary Intervention"],"prefix":"10.5551","volume":"25","author":[{"given":"Yun","family":"Wang","sequence":"first","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Ping Yen Yan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bruce Nichol","sequence":"additional","affiliation":[{"name":"Sol Price School of Public Policy, Leonard D. Schaeffer Center for Health Policy and Economics, Department of Pharmaceutical and Health Economics, School of Pharmacy, University of Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Wing Yan","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R and Baigent C: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (London, England), 2012; 380: 581-590","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R and Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (London, England), 2005; 366: 1267-1278","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J and Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England), 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Grundy S, Becker D, Clark L, Cooper R, Denke M, Howard J, Hunninghake D, Illingworth D, Luepker R and McBride P: The Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III or ATP III) guidelines for the management of serum lipids for high risk patients including those with a coronary artery disease equivalent[J]. Circulation, 2004; 109: 433-438","DOI":"10.1161\/01.CIR.0000111245.75752.C6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC and Stone NJ: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation, 2004; 110: 227-239","DOI":"10.1161\/01.CIR.0000133317.49796.0E"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U and Pedersen TR: 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J, 2016; 37: 2999-3058","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, ... and Graham I: 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 2016; 37: 2315-2381","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D and Lloyd-Jones DM: 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63: 2889-2934","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143","DOI":"10.1161\/circ.106.25.3143"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S and Huber K: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J, 2011; 32: 2999-3054","DOI":"10.1093\/eurheartj\/ehr236"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C and Chew DP: 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationTask Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J, 2016; 37: 267-315","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos G, Fonarow GC and Givertz MM: 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2016; 134: e282-e293","DOI":"10.1161\/CIR.0000000000000460"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Naito R, Miyauchi K and Daida H: Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb, 2017; 24: 19-25","DOI":"10.5551\/jat.RV16004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Leibowitz M, Karpati T, Cohen-Stavi CJ, Feldman BS, Hoshen M, Bitterman H, ... &amp; Balicer RD: Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Intern Med, 2016; 176: 1105-1113","DOI":"10.1001\/jamainternmed.2016.2751"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Li S, Zhang Y, Guo YL, Zhu CG, Wu NQ, Qing P, Gao Y, Sun J, Liu G and Dong Q: Effect of glycemic and lipid achievements on clinical outcomes type 2 diabetic, Chinese patients with stable coronary artery disease. J Diabetes Complications, 2016; 30: 115-120","DOI":"10.1016\/j.jdiacomp.2015.09.016"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Hamazaki T, Okuyama H, Ogushi Y, and Hama R: Towards a paradigm shift in cholesterol treatment. Ann Nutr Metab, 2015; 66: 1-116","DOI":"10.1159\/000381654"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Natsuaki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, Inada T, Mitsuoka H, Taniguchi R and Nakano A: Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Circulation J, 2012; 76: 1369-1379","DOI":"10.1253\/circj.CJ-11-1356"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Chinwong D, Patumanond J, Chinwong S, Siriwattana K, Gunaparn S, Hall JJ and Phrommintikul A: Low-density lipoprotein cholesterol of less than 70 mg\/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand. Ther Clin Risk Manag, 2015; 11: 659","DOI":"10.2147\/TCRM.S78745"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Yeh YT, Yin WH, Tseng WK, Lin FJ, Yeh HI, Chen JW, Wu YW and Wu CC: Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level?\u2014Data from a multicenter registry cohort study in Taiwan. PloS one, 2017; 12: e0186861","DOI":"10.1371\/journal.pone.0186861"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ahn T, Suh SY, Lee K, Kang WC, Han SH, Ahn Y and Jeong MH: Clinical Outcomes according to the Achievement of Target Low Density Lipoprotein-Cholesterol in Patients with Acute Myocardial Infarction. Korean Circ J, 2017; 47: 31-35","DOI":"10.4070\/kcj.2015.0266"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Lee VW, Chau RY, Cheung HY, Yu CM, Lam YY and Yan BP: How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong? BMC Cardiovasc Disord, 2015; 15: 117","DOI":"10.1186\/s12872-015-0117-y"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Wang Y, Yan BP, Nichol MB, Tomlinson B and Lee VWY: Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: A retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients. Int J Cardiol, 2017; 249: 18-24","DOI":"10.1016\/j.ijcard.2017.07.016"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Zhao SP: Amendment of the low-density lipoprotein cholesterol target in the \u2018Chinese Guidelines for the Prevention and Treatment of Adult Dyslipidemia&apos;: opinion. Chr diseases and translational medicine, 2016; 2: 7","DOI":"10.1016\/j.cdtm.2016.04.001"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Hu DY: New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China. Chron Dis Transl Med, 2017; 3: 73","DOI":"10.1016\/j.cdtm.2016.11.001"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Pearson TA, Laurora I, Chu H and Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med, 2000; 160: 459-467","DOI":"10.1001\/archinte.160.4.459"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hu M, Hooper AJ, van Bockxmeer FM, Watts GF, Chan JC and Tomlinson B: Management of familial hypercholesterolemia in Hong Kong. J Atheroscler Thromb, 2016; 23: 520-531","DOI":"10.5551\/jat.34314"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Chiang CE, Ferri\u00e8res J, Gotcheva NN, Raal FJ, Shehab A, Sung J, Henriksson KM and Hermans MP: Suboptimal control of lipid levels: results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb, 2016; 23: 567-587","DOI":"10.5551\/jat.31179"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Carlsson \u00c5, Borgstr\u00f6m F, St\u00e5lhammar J, Alemao E, Yin D and J\u00f6nsson L: Cost of care for patients treated with lipidlowering drugs. Pharmacoeconomics, 2004; 22: 25-35","DOI":"10.2165\/00019053-200422003-00004"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ganse EV, Laforest L, Alemao E, Davies G, Gutkin S and Yin D: Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin, 2005; 21: 1389-1399","DOI":"10.1185\/030079905X59139"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Tomlinson B, Chan P and Liu ZM: Statin Responses in Chinese Patients. J Atheroscler Thromb, 2018; 25: 199-202","DOI":"10.5551\/jat.40204"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Chin CW, Gao F, Le T and Tan R: Lipid goal attainment and prescription behavior in asian patients with acute coronary syndromes: experience from a tertiary hospital. Clin Med Insights Cardiol, 2013; 7: 51","DOI":"10.4137\/CMC.S11488"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kim HS, Wu Y, Lin SJ, Deerochanawong C, Zambahari R, Zhao L, Zhang Q and Yan P: Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin, 2008; 24: 1951-1963","DOI":"10.1185\/03007990802138731"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A and Di Sciascio G: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol, 2007; 49: 1272-1278","DOI":"10.1016\/j.jacc.2007.02.025"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Carey JS, Danielsen B, Junod FL, Rossiter SJ and Stabile BE: The California Cardiac Surgery and Intervention Project: evolution of a public reporting program. Am Surg, 2006; 72: 978-983","DOI":"10.1177\/000313480607201031"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Harjai KJ, Singh M and Boura J: Early readmissions after percutaneous coronary intervention in a rural tertiary care center (from the Guthrie Health Off-label Stent [GHOST] Registry). Am J Cardiol, 2012; 110: 491-497","DOI":"10.1016\/j.amjcard.2012.04.022"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Kim HL, Kang SH, Yoon CH, Cho YS, Youn TJ, Cho GY, Chae IH, Kim HS, Chae SC and Cho MC: Differential prognostic impacts of diabetes over time course after acute myocardial infarction. J Korean Med Sci, 2013; 28: 1749-1755","DOI":"10.3346\/jkms.2013.28.12.1749"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Rade JJ and Hogue CW: Noncardiac Surgery for Patients with Coronary Artery StentsTiming Is Everything. Anesthesiology, 2008; 109: 573-575","DOI":"10.1097\/ALN.0b013e3181870a4b"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Hermiller JB, Rutledge DR, Mao VW, Zhao W, Wang J, Gruberg L, Lombardi W, Sharma SK and Krucoff MW: Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V<sup>\u00ae<\/sup> everolimus-eluting stents: One year results from the XIENCE V<sup>\u00ae<\/sup> USA condition of approval post-market study. Catheter Cardiovasc Interv, 2014; 84: 7-16","DOI":"10.1002\/ccd.25325"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Zhao Z, Zhu Y, Fang Y and McCollam P: Health Care Costs And Resource Utilization In Working Age Patients With High Risk Vascular Disease: Findings From A Multi-Employer Claims Database. Value Health, 2014; 17: A111","DOI":"10.1016\/j.jval.2014.03.646"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Korsnes JS: Evaluation Of Hospital Resource Utilization Associated With Major Adverse Cardiovascular Events. Value Health, 2014; 17: A111-A112","DOI":"10.1016\/j.jval.2014.03.650"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Harriss LR, Ajani AE, Hunt D, Shaw J, Chambers B, Dewey H, Frayne J, Beauchamp A, Duv\u00e9 K and Giles GG: Accuracy of national mortality codes in identifying adjudicated cardiovascular deaths. Aust N Z J Public Health, 2011; 35: 466-476","DOI":"10.1111\/j.1753-6405.2011.00739.x"},{"key":"42","unstructured":"42) World Health Organization: Choosing interventions that are cost effective (WHO-CHOICE): country-specific unit costs. 2014"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Chang AM, Ho J, Yan BP, Yu CM, Lam YY and Lee VW: Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation\u2014A Real Patient Data Analysis in a Hong Kong Teaching Hospital. Clin Cardiol, 2013; 36: 280-285","DOI":"10.1002\/clc.22112"},{"key":"44","unstructured":"44) The Hong Kong Association of Banks. Exchange rates. 2018"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Cattaneo MD: Efficient semiparametric estimation of multivalued treatment effects under ignorability. J Econom, 2010; 155: 138-154","DOI":"10.1016\/j.jeconom.2009.09.023"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Imbens GW: The role of the propensity score in estimating dose-response functions. Biometrika, 2000; 87: 706- 710","DOI":"10.1093\/biomet\/87.3.706"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Austin PC, Ghali WA and Tu JV: A comparison of several regression models for analysing cost of CABG surgery. Stat Med, 2003; 22: 2799-2815","DOI":"10.1002\/sim.1442"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Gaziano JM, Hennekens CH, Satterfield S, Roy C, Sesso HD, Breslow JL and Buring JE: Clinical utility of lipid and lipoprotein levels during hospitalization for acute myocardial infarction. Vasc Med, 1999; 4: 227-231","DOI":"10.1177\/1358836X9900400404"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50) Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman D, Kinosian B and Weinstein MC: Cost and health implications of cholesterol lowering. Circulation, 1992; 85: 1960-1968","DOI":"10.1161\/01.CIR.85.5.1960"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/12\/25_44818\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T17:09:11Z","timestamp":1604509751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/12\/25_44818\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.44818","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}